Clinical Trial Update: Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial comparing bevacizumab plus temsirolimus versus bevacizumab plus interferon-alfa in advanced renal cell carcinoma. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Interferon Alfa (interferon alfa)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2013-06-04